Keck School Faculty

Guy A. Young

Guy A. Young

Professor of Pediatrics (Clinical Scholar)
Pediatrics CHLA
CHL Mail Stop 54 Off Campus Los Angeles

National Hemophilia Foundation: Physician of the Year, 2013

Time to revisit the classification of hemophilia: if it ain't broke, don't fix it! J Thromb Haemost 2023 Jul; 21(7):1755-1756. . View in PubMed

The dosing conundrum of emicizumab: To waste product or not? Res Pract Thromb Haemost. 2023 Feb; 7(2):100087.. View in PubMed

Evaluation of venous thromboembolism risk factors reveals subtype heterogenicity in children with central venous catheters: a multicenter study from the Children's Hospital Acquired Thrombosis consortium J Thromb Haemost. 2023 09; 21(9):2441-2450. . View in PubMed

Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding Expert Rev Hematol. 2023 03; 16(sup1):107-127. . View in PubMed

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B N Engl J Med. 2023 02 23; 388(8):706-718. . View in PubMed

Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial Lancet. 2023 04 29; 401(10386):1427-1437. . View in PubMed

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A Blood Adv. 2023 02 28; 7(4):620-629. . View in PubMed

Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab Haemophilia. 2022 Oct 26. . View in PubMed

Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital-Acquired Thrombosis consortium Res Pract Thromb Haemost. 2022 Oct; 6(7):e12810. . View in PubMed

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies Blood Adv. 2022 Aug 08. . View in PubMed

Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors Haemophilia. 2022 Jul; 28(4):548-556. . View in PubMed

Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response Thromb Haemost. 2022 Jun; 122(6):913-925. . View in PubMed

Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life J Adv Pract Oncol. 2022 May; 13(Suppl 3):7-20. . View in PubMed

Risk factors for hospital acquired venous thromboembolism in congenital heart disease patients: A report from the children's hospital acquired thrombosis (CHAT) consortium Thromb Res. 2022 12; 220:116-120. . View in PubMed

Direct oral anticoagulants for use in paediatrics Lancet Child Adolesc Health. 2022 03; 6(3):207-214. . View in PubMed

Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia Pediatr Blood Cancer. 2022 03; 69(3):e29522. . View in PubMed

Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium J Thromb Haemost. 2022 01; 20(1):133-137. . View in PubMed

Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children J Pediatr. 2022 01; 240:14-23. . View in PubMed

Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A Haemophilia. 2022 Jan; 28(1):27-35. . View in PubMed

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors Blood Adv. 2022 06 14; 6(11):3422-3432. . View in PubMed

A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium Pediatr Crit Care Med. 2022 01 01; 23(1):e1-e9. . View in PubMed

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors Haemophilia. 2021 Nov; 27(6):921-931. . View in PubMed

Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making Haemophilia. 2021 Sep; 27(5):724-729. . View in PubMed

Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays Haemophilia. 2021 Sep; 27(5):730-735. . View in PubMed

Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A Expert Opin Drug Saf. 2021 Apr; 20(4):387-396. . View in PubMed

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study Thromb Haemost. 2021 Mar; 121(3):351-360. . View in PubMed

Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders Haemophilia. 2021 Mar; 27(2):211-220. . View in PubMed

Emerging drugs for hemophilia A: insights into phase II and III clinical trials Expert Opin Emerg Drugs. 2021 12; 26(4):337-350. . View in PubMed

Management of children with hemophilia A: How emicizumab has changed the landscape J Thromb Haemost. 2021 07; 19(7):1629-1637. . View in PubMed

Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors Expert Rev Hematol. 2021 02; 14(2):143-148. . View in PubMed

Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis ConsortiumJ Pediatr. 2021 01; 228:252-259. e1. . View in PubMed

Comparison of bypassing agents in patients on emicizumab using global hemostasis assays Haemophilia. 2021 Jan; 27(1):164-172. . View in PubMed

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression Blood. 2021 02 11; 137(6):763-774. . View in PubMed

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies Blood. 2021 04 22; 137(16):2231-2242. . View in PubMed

Can we do something about ICH in hemophilia? Blood. 2021 12 30; 138(26):2750-2751.. View in PubMed

Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study Haemophilia. 2020 Nov; 26(6):1009-1018. . View in PubMed

Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients Res Pract Thromb Haemost. 2020 Oct; 4(7):1101-1113. . View in PubMed

The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease Res Pract Thromb Haemost. 2020 Jul; 4(5):886-892. . View in PubMed

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study Haemophilia. 2020 May; 26(3):494-502. . View in PubMed

Implications of the first FDA-approved anticoagulant in pediatrics: One ship has sailed but the next ones are at the dock Pediatr Blood Cancer. 2020 12; 67(12):e28731. . View in PubMed

Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child Pediatrics. 2020 11; 146(5). . View in PubMed

Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation J Thromb Haemost. 2020 09; 18(9):2205-2208. . View in PubMed

FondaKIDS III: A long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children Pediatr Blood Cancer. 2020 08; 67(8):e28295. . View in PubMed

Rivaroxaban for treatment of pediatric venous thromboembolismAn Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020 07; 18(7):1672-1685. . View in PubMed

Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms Expert Rev Hematol. 2020 04; 13(4):313-321. . View in PubMed

Comparative validation study of risk assessment models for pediatric hospital-acquired venous thromboembolism J Thromb Haemost. 2020 03; 18(3):633-641. . View in PubMed

Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE) Blood Adv. 2020 10 13; 4(19):4632-4639. . View in PubMed

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial Lancet Haematol. 2020 Jan; 7(1):e18-e27. . View in PubMed

Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children Blood. 2020 01 16; 135(3):220-226. . View in PubMed

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies Lancet Haematol. 2019 Oct; 6(10):e500-e509. . View in PubMed

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab Haemophilia. 2019 Jul; 25(4):676-684. . View in PubMed

Diagnosis and treatment of hemophilia Clin Adv Hematol Oncol. 2019 Jun; 17(6):344-351. . View in PubMed

Why plasma-derived factor VIII? Haemophilia. 2019 May; 25(3):e183-e185.. View in PubMed

Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice J Thromb Haemost. 2019 Apr; 17(4):567-573. . View in PubMed

How I treat children with haemophilia and inhibitors Br J Haematol. 2019 08; 186(3):400-408. . View in PubMed

Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia Am J Hematol. 2019 02; 94(2):249-256. . View in PubMed

Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays Ther Adv Hematol. 2019; 10:2040620719860025. . View in PubMed

Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data J Blood Med. 2019; 10:243-250. . View in PubMed

Inhibitors: A Need for Eradication? Acta Haematol. 2019; 141(3):151-155.. View in PubMed

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors Blood. 2019 12 12; 134(24):2127-2138. . View in PubMed

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results Blood. 2019 11 28; 134(22):1973-1982. . View in PubMed

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study Haemophilia. 2019 Jan; 25(1):33-44. . View in PubMed

Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials Haemophilia. 2018 Nov; 24(6):911-920. . View in PubMed

Novel therapies and current clinical progress in hemophilia A Ther Adv Hematol. 2018 Feb; 9(2):49-61. . View in PubMed

Emicizumab for hemophilia A with factor VIII inhibitors Expert Rev Hematol. 2018 11; 11(11):835-846. . View in PubMed

The importance of inhibitor eradication in clinically complicated hemophilia A patients Expert Rev Hematol. 2018 11; 11(11):857-862. . View in PubMed

Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia Thromb Res. 2018 05; 165:44-50. . View in PubMed

Deep vein thrombosis in pediatric patients Pediatr Blood Cancer. 2018 03; 65(3). . View in PubMed

A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies Expert Rev Hematol. 2018 02; 11(2):87-97. . View in PubMed

A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) project Thromb Res. 2018 01; 161:67-72. . View in PubMed

Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance Blood Adv. 2018 10 23; 2(20):2780-2782. . View in PubMed

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhoodDesign of the EINSTEIN-Jr phase III study. Thromb J. 2018; 16:34. . View in PubMed

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study Thromb J. 2018; 16:31. . View in PubMed

Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries Am J Hematol. 2017 Sep; 92(9):940-945. . View in PubMed

Thromboelastographic characterization of the activated clotting system in children with sickle cell trait or sickle cell disease Thromb Res. 2017 Mar; 151:44-50. . View in PubMed

Anticoagulation Therapies in Children Pediatr Clin North Am. 2017 12; 64(6):1257-1269. . View in PubMed

Pediatric Anticoagulation: Time for a New Paradigm? J Pediatr. 2017 10; 189:21-23.. View in PubMed

Anticoagulation in children: Making the most of little patients and little evidence Blood Cells Mol Dis. 2017 09; 67:48-53. . View in PubMed

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates Thromb Haemost. 2017 06 02; 117(6):1023-1030. . View in PubMed

Emicizumab Prophylaxis in Hemophilia A with Inhibitors N Engl J Med. 2017 08 31; 377(9):809-818. . View in PubMed

How I treat pediatric venous thromboembolism Blood. 2017 09 21; 130(12):1402-1408. . View in PubMed

Treatment of Venous Thromboembolism in Pediatric Patients Front Pediatr. 2017; 5:26. . View in PubMed

Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study Br J Haematol. 2016 Oct; 175(1):133-40. . View in PubMed

The past and future of haemophilia: diagnosis, treatments, and its complications Lancet. 2016 Jul 09; 388(10040):187-97. . View in PubMed

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A N Engl J Med. 2016 May 26; 374(21):2054-64. . View in PubMed

Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4) Thromb Res. 2016 May; 141:69-76. . View in PubMed

The bleeding newborn: A review of presentation, diagnosis, and management Semin Fetal Neonatal Med. 2016 Feb; 21(1):44-9. . View in PubMed

The perils of rivaroxaban in younger patients Thromb Res. 2016 12; 148:154-155. . View in PubMed

Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A Thromb Haemost. 2016 07 04; 116(1):1-8. . View in PubMed

Global assays in hemophilia Semin Hematol. 2016 Jan; 53(1):40-5. . View in PubMed

Understanding patient preferences and willingness to pay for hemophilia therapies Patient Prefer Adherence. 2015; 9:1623-30. . View in PubMed

Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors Clin Appl Thromb Hemost. 2015 Jan; 21(1):10-8. . View in PubMed

Anticoagulants in children and adolescents Hematology Am Soc Hematol Educ Program. 2015; 2015:111-6. . View in PubMed

Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial Blood. 2014 Dec 18; 124(26):3880-6. . View in PubMed

FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events Thromb Res. 2014 Sep; 134(3):643-7. . View in PubMed

Developmental hemostasis: clinical implications from the fetus to the adolescent Pediatr Clin North Am. 2013 Dec; 60(6):1407-17. . View in PubMed

Incidence of thrombosis in children with tunneled central venous access devices versus peripherally inserted central catheters (PICCs) Thromb Res. 2013 Nov; 132(5):527-30. . View in PubMed

Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients Clin Pharmacokinet. 2013 Nov; 52(11):967-80. . View in PubMed

Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation J Pediatr Surg. 2013 Sep; 48(9):1837-42. . View in PubMed

A novel approach for detecting hypercoagulability utilizing thromboelastography Thromb Res. 2013 Apr; 131(4):352-6. . View in PubMed

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives Blood. 2013 Mar 14; 121(11):1944-50. . View in PubMed

Factor VIII inhibitors in hemophilia A: rationale and latest evidence Ther Adv Hematol. 2013 Feb; 4(1):59-72. . View in PubMed

PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors Thromb Res. 2012 Dec; 130(6):864-70. . View in PubMed

Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008) Haemophilia. 2012 Nov; 18(6):990-6. . View in PubMed

Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A Am J Hematol. 2012 Sep; 87(9):933-6. . View in PubMed

Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children Expert Rev Clin Pharmacol. 2012 Jul; 5(4):389-96. . View in PubMed

Difficult clinical challenges in haemophilia: international experiential perspectives Haemophilia. 2012 Jul; 18 Suppl 5:39-45. . View in PubMed

From boy to man: recommendations for the transition process in haemophilia Haemophilia. 2012 Jul; 18 Suppl 5:27-32. . View in PubMed

Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE) Haemophilia. 2012 May; 18(3):392-9. . View in PubMed

New challenges in hemophilia: long-term outcomes and complications Hematology Am Soc Hematol Educ Program. 2012; 2012:362-8. . View in PubMed

Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE) J Blood Med. 2012; 3:131-8. . View in PubMed

FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age Pediatr Blood Cancer. 2011 Dec 01; 57(6):1049-54. . View in PubMed

Old and new antithrombotic drugs in neonates and infants Semin Fetal Neonatal Med. 2011 Dec; 16(6):349-54. . View in PubMed

Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis Semin Thromb Hemost. 2011 Oct; 37(7):802-9. . View in PubMed

When should prophylaxis therapy in inhibitor patients be considered? Haemophilia. 2011 Sep; 17(5):e849-57.. View in PubMed

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors Am Health Drug Benefits. 2011 Jul; 4(4):219-31. . View in PubMed

Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study Pediatr Blood Cancer. 2011 Jul 01; 56(7):1103-9. . View in PubMed

Pediatric catheterization laboratory anticoagulation with bivalirudin Catheter Cardiovasc Interv. 2011 Apr 01; 77(5):671-9. . View in PubMed

New anticoagulants in children: a review of recent studies and a look to the future Thromb Res. 2011 Feb; 127(2):70-4. . View in PubMed

Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics J Clin Pharmacol. 2011 Jan; 51(1):19-28. . View in PubMed

Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population Blood Coagul Fibrinolysis. 2010 Sep; 21 Suppl 1:S7-10. . View in PubMed

Comparison of kaolin and tissue factor activated thromboelastography in haemophilia Haemophilia. 2010 May; 16(3):518-24. . View in PubMed

Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies Circulation. 2010 Apr 27; 121(16):1838-47. . View in PubMed

Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children Pediatr Blood Cancer. 2009 Aug; 53(2):179-83. . View in PubMed

Bivalirudin for anticoagulation in children Pediatr Blood Cancer. 2008 Dec; 51(6):798-801. . View in PubMed

Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies Circulation. 2008 Sep 23; 118(13):1373-82. . View in PubMed

Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial Blood Coagul Fibrinolysis. 2008 Jun; 19(4):276-82. . View in PubMed

Single 270 microg kg(-1)-dose rFVIIa vsstandard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008 Mar; 14(2):287-94. . View in PubMed

New anticoagulants in children Hematology Am Soc Hematol Educ Program. 2008; 245-50. . View in PubMed

Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography Blood Coagul Fibrinolysis. 2007 Sep; 18(6):547-53. . View in PubMed

Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis J Thromb Haemost. 2007 Aug; 5(8):1654-9. . View in PubMed

Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation Blood Coagul Fibrinolysis. 2007 Mar; 18(2):97-103. . View in PubMed

Heparin use in children Pediatr Res. 2007 Feb; 61(2):139-40. . View in PubMed

Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency Blood. 2006 Jul 01; 108(1):57-62. . View in PubMed

Diagnosis and treatment of thrombosis in children: general principles Pediatr Blood Cancer. 2006 May 01; 46(5):540-6. . View in PubMed

Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children J Pediatr. 2006 Apr; 148(4):489-94. . View in PubMed

New approaches in the management of inhibitor patients Acta Haematol. 2006; 115(3-4):172-9. . View in PubMed

Multifocal Castleman disease in pediatrics: case report J Pediatr Hematol Oncol. 2005 Dec; 27(12):666-9. . View in PubMed

Pediatric stroke and methylenetetrahydrofolate reductase polymorphisms: an examination of C677T and A1298C mutations J Pediatr Hematol Oncol. 2005 Nov; 27(11):590-3. . View in PubMed

Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome Genet Med. 2005 Feb; 7(2):143-6. . View in PubMed

Therapy for haemophilia: recent advances and goals for the future Expert Opin Emerg Drugs. 2005 Feb; 10(1):173-84. . View in PubMed

Can we rise to yet another challenge? Prof Nurse. 2004 Sep; 20(1):6-7.. View in PubMed

Current and future antithrombotic agents in children Expert Rev Cardiovasc Ther. 2004 Jul; 2(4):523-34. . View in PubMed

Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits Perfusion. 2004; 19(5):283-8. . View in PubMed

Following medical school, I completed my residency in pediatrics at Schneider Children's Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children's Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children's Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.
sc ctsi logoPowered by SC CTSI